PMID- 19735869
OWN - NLM
STAT- MEDLINE
DCOM- 20090921
LR  - 20151119
IS  - 1879-355X (Electronic)
IS  - 0360-3016 (Linking)
VI  - 75
IP  - 2
DP  - 2009 Oct 1
TI  - Usefulness of HIF-1 imaging for determining optimal timing of combining 
      bevacizumab and radiotherapy.
PG  - 463-7
LID - 10.1016/j.ijrobp.2009.02.083 [doi]
AB  - PURPOSE: To study the relationship between the hypoxia-inducible factor-1 (HIF-1) 
      activity level after bevacizumab treatment and the antitumor effects of radiation 
      to determine the optimal combination schedule of bevacizumab with radiotherapy. 
      METHODS AND MATERIALS: The tumor hypoxia changes induced after bevacizumab 
      treatment were evaluated using optical imaging with a HIF-1-dependent reporter 
      gene using the NCI-H441 human lung adenocarcinoma xenograft model. The combined 
      effects of bevacizumab with radiation were evaluated according to the timing of 
      combination. RESULTS: In vivo imaging experiments revealed that bevacizumab 
      treatment had little effect on intratumoral HIF-1 activity 1 day after 
      bevacizumab treatment, but it dramatically upregulated it thereafter through 
      increases in the hypoxic fractions of the tumors. When bevacizumab treatment was 
      combined with 14 Gy of radiation at 24 h or 72 h after bevacizumab treatment, the 
      former combination delayed, but the latter combination accelerated, tumor growth 
      compared with irradiation alone. CONCLUSION: These data suggest that an optimal 
      window exists for combining bevacizumab with radiotherapy that determines whether 
      the combination will be beneficial and that the imaging of HIF-1 activity would 
      be useful in determining this window.
FAU - Ou, Guangfei
AU  - Ou G
AD  - Department of Radiation Oncology, Cancer Hospital Institute, Chinese Academy of 
      Medical Science and Peking Union Medical College, Beijing, People's Republic of 
      China.
FAU - Itasaka, Satoshi
AU  - Itasaka S
FAU - Zeng, Lihua
AU  - Zeng L
FAU - Shibuya, Keiko
AU  - Shibuya K
FAU - Yi, Junlin
AU  - Yi J
FAU - Harada, Hiroshi
AU  - Harada H
FAU - Hiraoka, Masahiro
AU  - Hiraoka M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Radiat Oncol Biol Phys
JT  - International journal of radiation oncology, biology, physics
JID - 7603616
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers)
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - *Adenocarcinoma/blood supply/drug therapy/metabolism/radiotherapy
MH  - Angiogenesis Inhibitors/*administration & dosage
MH  - Animals
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Bevacizumab
MH  - Biomarkers/metabolism
MH  - *Cell Hypoxia/drug effects
MH  - Cell Line, Tumor
MH  - Combined Modality Therapy/methods
MH  - Genes, Reporter
MH  - Humans
MH  - Hypoxia-Inducible Factor 1/genetics/*metabolism
MH  - In Situ Nick-End Labeling
MH  - *Lung Neoplasms/blood supply/drug therapy/metabolism/radiotherapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Random Allocation
MH  - Time Factors
MH  - Xenograft Model Antitumor Assays
EDAT- 2009/09/09 06:00
MHDA- 2009/09/22 06:00
CRDT- 2009/09/09 06:00
PHST- 2008/09/21 00:00 [received]
PHST- 2009/02/04 00:00 [revised]
PHST- 2009/02/04 00:00 [accepted]
PHST- 2009/09/09 06:00 [entrez]
PHST- 2009/09/09 06:00 [pubmed]
PHST- 2009/09/22 06:00 [medline]
AID - S0360-3016(09)00847-5 [pii]
AID - 10.1016/j.ijrobp.2009.02.083 [doi]
PST - ppublish
SO  - Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):463-7. doi: 
      10.1016/j.ijrobp.2009.02.083.